BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

BioAtla, Inc. announced that the US FDA had cleared its IND application to evaluate BA3182 for the treatment of advanced adenocarcinoma. BioAtla planned to initiate and advance a Phase I dose-escalation and expansion clinical study in 2023.